While in SkOVi31 model, there was also notable reduction of tumor growth in EphA2-FAK-siRNA-DOPC (76%)-treated group compared to the EphA2- (50%) and FAK- (61%) treated group. This evidence concerns the gene EPHA2 and neoplasm.